Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 15  |  Issue : 8  |  Page : 87--90

Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience


Gul Kanyilmaz1, Irem Saricanbaz2, Huseyin Bora3, Eray Karahacioglu3, Eda Yirmibesoglu Erkal4 
1 Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Konya, Turkey
2 Department of Radiation Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey
3 Department of Radiation Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
4 Department of Radiation Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey

Correspondence Address:
Dr. Gul Kanyilmaz
Department of Radiation Oncology, Necmettin Erbakan University Meram Medicine School, Akyokus Mevkii, Konya
Turkey

Objectives: There is no consensus regarding the management of Stage 1 seminomas following inguinal orchiectomy. In this study, we evaluated the treatment results and treatment-related toxicity for patients with Stage 1 seminomas treated with adjuvant radiotherapy (RT) at a single institution. Methods: Sixty-five patients who underwent adjuvant RT following orchiectomy for Stage 1 seminomas between January 1996 and December 2007 were retrospectively reviewed. The age, tumor location, histopathological type, stage, tumor size, RT field, and radiation dose were recorded for all patients. Results: The patients' ages ranged from 17 to 61 years (median, 37 years). Sixty-three patients (97%) were diagnosed with classical seminoma and the remaining two patients (3%) had spermatocytic seminoma. After orchiectomy, 37 patients (57%) received para-aortic RT and 28 patients (43%) received dog-leg field RT. RT was applied with 1.8–2 Gy/day fractionation and the median RT dose was 26 Gy (range, 20–38). Follow-up ranged from 0.3 to 18 years (median, 9.5 years). Local control had been achieved in all patients and all of them were alive with no evidence of disease. Fifty-one patients (77%) had at least 5 years of follow-up and 27 patients (41%) had at least 10 years of follow-up. Overall survival at 10 years was 100%. Conclusion: Although retrospective in nature, this single-institutional study provides useful information about the outcomes and toxicities associated with adjuvant RT in patients with Stage 1 seminomas reporting excellent disease control and survival rates at the expense of acceptable toxicity.


How to cite this article:
Kanyilmaz G, Saricanbaz I, Bora H, Karahacioglu E, Erkal EY. Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience.J Can Res Ther 2019;15:87-90


How to cite this URL:
Kanyilmaz G, Saricanbaz I, Bora H, Karahacioglu E, Erkal EY. Adjuvant radiotherapy for Stage I seminoma: A Single-institutional experience. J Can Res Ther [serial online] 2019 [cited 2021 Jan 25 ];15:87-90
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2019;volume=15;issue=8;spage=87;epage=90;aulast=Kanyilmaz;type=0